India's Zydus Cadila spies opportunity in large diabetes market

2 August 2019

Ahmedabad-based Zydus Cadila has reported positive top-line results from a Phase III trial of Lipaglyn (saroglitazar) for treating type 2 diabetes. The therapy has been approved in India to treat diabetes-related conditions since 2013.

The primary outcome of the trial was a change from baseline in HbA1c at 24 weeks. No severe hypoglycemia events were reported, and there was no weight gain or edema observed.

Chairman Pankaj Patel said: “Insulin resistance is the root cause of type 2 diabetes mellitus and the data from this trial reveals that saroglitazar, a next-generation insulin sensitizer without the edema and weight gain side effects, could emerge as a potent anti-diabetic agent for millions of patients suffering from type 2 diabetes.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK